Citations (80)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (18)
Masaru Tsuchikawa & Kentaro Sakamaki. (2023) Estimands for Continuous Longitudinal Outcomes in the Presence of Treatment Discontinuation—A Simulation Study in Hyperkalemia Treatments. Statistics in Biopharmaceutical Research 15:2, pages 359-371.
Read now
Read now
Jaap N.E. Bakers, Adriaan D. de Jongh, Tommy M. Bunte, Lindsay Kendall, Steve S. Han, Noam Epstein, Arseniy Lavrov, Anita Beelen, Johanna M.A. Visser-Meily, Leonard H. van den Berg & Ruben P. A. van Eijk. (2022) Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 23:7-8, pages 500-507.
Read now
Read now
Yingying Liu, Bo Lu, Richard Foster, Yiwei Zhang, Z. John Zhong, Ming-Hui Chen & Peng Sun. (2022) Matching design for augmenting the control arm of a randomized controlled trial using real-world data. Journal of Biopharmaceutical Statistics 32:1, pages 124-140.
Read now
Read now
Ruben P.A. van Eijk, Adriaan D. de Jongh, Stavros Nikolakopoulos, Christopher J. McDermott, Marinus J.C. Eijkemans, Kit C.B. Roes & Leonard H. van den Berg. (2021) An old friend who has overstayed their welcome: the ALSFRS-R total score as primary endpoint for ALS clinical trials. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 22:3-4, pages 300-307.
Read now
Read now
Stephen A. Goutman, Morton B. Brown, Merit Cudkowicz, Nazem Atassi & Eva L. Feldman. (2019) ALS/SURV: a modification of the CAFS statistic. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 20:7-8, pages 576-583.
Read now
Read now
Ruben PA van Eijk, Marinus JC Eijkemans, Dimitris Rizopoulos, Leonard H van den Berg & Stavros Nikolakopoulos. (2018) Comparing methods to combine functional loss and mortality in clinical trials for amyotrophic lateral sclerosis. Clinical Epidemiology 10, pages 333-341.
Read now
Read now
Jeremy M. Shefner, Seward B. Rutkove, James B. Caress, Michael Benatar, William S. David, Michael S. Cartwright, Eric A. Macklin & Jose L. Bohorquez. (2018) Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 19:7-8, pages 555-561.
Read now
Read now
Koji Takei, Kikumi Tsuda, Fumihiro Takahashi & Joseph Palumbo. (2017) Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 64-70.
Read now
Read now
Nicholas J. Maragakis. (2017) What can we learn from the edaravone development program for ALS?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 98-103.
Read now
Read now
Koji Takei, Fumihiro Takahashi, Shawn Liu, Kikumi Tsuda & Joseph Palumbo. (2017) Post-hoc analysis of randomised, placebo-controlled, double-blind study (MCI186-19) of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:sup1, pages 49-54.
Read now
Read now
ÉIlis J. O’Reilly, Dawei Liu, Donald R. Johns, Merit E. Cudkowicz, Sabrina Paganoni, Michael A. Schwarzschild, Melanie Leitner & Alberto Ascherio. (2017) Serum urate at trial entry and ALS progression in EMPOWER. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 18:1-2, pages 120-125.
Read now
Read now
Malcolm Proudfoot, Ashley Jones, Kevin Talbot, Ammar Al-Chalabi & Martin R. Turner. (2016) The ALSFRS as an outcome measure in therapeutic trials and its relationship to symptom onset. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 17:5-6, pages 414-425.
Read now
Read now
H Blasco, F Patin, CR Andres, P Corcia & PH Gordon. (2016) Amyotrophic Lateral Sclerosis, 2016: existing therapies and the ongoing search for neuroprotection. Expert Opinion on Pharmacotherapy 17:12, pages 1669-1682.
Read now
Read now
Hazuki Watanabe, Naoki Atsuta, Ryoichi Nakamura, Akihiro Hirakawa, Hirohisa Watanabe, Mizuki Ito, Jo Senda, Masahisa Katsuno, Yuishin Izumi, Mitsuya Morita, Hiroyuki Tomiyama, Akira Taniguchi, Ikuko Aiba, Koji Abe, Kouichi Mizoguchi, Masaya Oda, Osamu Kano, Koichi Okamoto, Satoshi Kuwabara, Kazuko Hasegawa, Takashi Imai, Masashi Aoki, Shoji Tsuji, Imaharu Nakano, Ryuji Kaji & Gen Sobue. (2015) Factors affecting longitudinal functional decline and survival in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 16:3-4, pages 230-236.
Read now
Read now
Namita A Goyal & Tahseen Mozaffar. (2014) Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs. Expert Opinion on Investigational Drugs 23:11, pages 1541-1551.
Read now
Read now
Michael E. Bozik, Hiroshi Mitsumoto, Benjamin R. Brooks, Stacy A. Rudnicki, Dan H. Moore, Bing Zhang, Albert Ludolph, Merit E. Cudkowicz, Leonard H. van den Berg, James Mather, Thomas Petzinger$suffix/text()$suffix/text() & Donald Archibald. (2014) A post hoc analysis of subgroup outcomes and creatinine in the phase III clinical trial (EMPOWER) of dexpramipexole in ALS. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:5-6, pages 406-413.
Read now
Read now
James D. Berry, Merit E. Cudkowicz & Jeremy M. Shefner. (2014) Predicting success: Optimizing phase II ALS trials for the transition to phase III. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 15:1-2, pages 1-8.
Read now
Read now
Jeffrey Rosenfeld. (2013) What are we measuring?. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration 14:3, pages 161-161.
Read now
Read now
Articles from other publishers (62)
Jiongming Bai, Xiaolan Zhang, Haoran Wang, Wenxiu Yu, Zhengqing He, Jiao Wang, Feng feng, Mao Li, Hongfen Wang, Fei Yang & Xusheng Huang. (2023) Gender-specific association of uric acid and survival in sporadic amyotrophic lateral sclerosis patients. Brain Research 1815, pages 148445.
Crossref
Crossref
Kjetil BjornevikMarianna CorteseJeremy D. FurtadoSabrina PaganoniMichael A. SchwarzschildMerit E. CudkowiczAlberto Ascherio. (2023) Association of Polyunsaturated Fatty Acids and Clinical Progression in Patients With ALS. Neurology 101:7.
Crossref
Crossref
Michael Benatar, Joanne Wuu & Martin R Turner. (2023) Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal. Brain 146:7, pages 2711-2716.
Crossref
Crossref
Melanie Quintana, Benjamin R. Saville, Matteo Vestrucci, Michelle A. Detry, Lori Chibnik, Jeremy Shefner, James D. Berry, Marianne Chase, Jinsy Andrews, Alexander V. Sherman, Hong Yu, Kristin Drake, Merit Cudkowicz, Sabrina Paganoni & Eric A. Macklin. (2023) Design and Statistical Innovations in a Platform Trial for Amyotrophic Lateral Sclerosis. Annals of Neurology.
Crossref
Crossref
Satoru Morimoto, Shinichi Takahashi, Daisuke Ito, Yugaku Daté, Kensuke Okada, Chris Kato, Shiho Nakamura, Fumiko Ozawa, Chai Muh Chyi, Ayumi Nishiyama, Naoki Suzuki, Koki Fujimori, Tosho Kondo, Masaki Takao, Miwa Hirai, Yasuaki Kabe, Makoto Suematsu, Masahiro Jinzaki, Masashi Aoki, Yuto Fujiki, Yasunori Sato, Norihiro Suzuki, Jin Nakahara & Hideyuki Okano. (2023) Phase 1/2a clinical trial in ALS with ropinirole, a drug candidate identified by iPSC drug discovery. Cell Stem Cell 30:6, pages 766-780.e9.
Crossref
Crossref
Steve Vucic, Parvathi Menon, William Huynh, Colin Mahoney, Karen S. Ho, Alan Hartford, Austin Rynders, Jacob Evan, Jeremy Evan, Shelia Ligozio, Robert Glanzman, Michael T. Hotchkin & Matthew C. Kiernan. (2023) Efficacy and safety of CNM-Au8 in amyotrophic lateral sclerosis (RESCUE-ALS study): a phase 2, randomised, double-blind, placebo-controlled trial and open label extension. eClinicalMedicine 60, pages 102036.
Crossref
Crossref
Siddhartha Datta, Zubin Rashid, Saptarnab Naskar & Sumantra Chattarji. (2023) Administration of the glutamate-modulating drug, riluzole, after stress prevents its delayed effects on the amygdala in male rats. PNAS Nexus 2:6.
Crossref
Crossref
David Walk, Katharine Nicholson, Eduardo Locatelli, James Chan, Eric A. Macklin, Valerie Ferment, Georgios Manousakis, Marianne Chase, Mariah Connolly, Derek Dagostino, Meghan Hall, Joseph Ostrow, Lindsay Pothier, Cassandra Lieberman, Dario Gelevski, Rebecca Randall, Alexander V. Sherman, Erin Steinhart, Daniela Grasso Walker, Jason Walker, Hong Yu, Anne‐Marie Wills, Michael A. Schwarzschild, Anna L. Beukenhorst, Jukka‐Pekka Onnela, James D. Berry, Merit E. Cudkowicz & Sabrina Paganoni. (2023) Randomized trial of inosine for urate elevation in amyotrophic lateral sclerosis. Muscle & Nerve 67:5, pages 378-386.
Crossref
Crossref
Angelika Caputo, Amy Racine, Ines Paule, Pierre N. Tariot, Jessica B. Langbaum, Neva Coello, Marie-Emmanuelle Riviere, J. Michael Ryan, Cristina Lopez Lopez & Ana Graf. (2023) Rationale for the selection of dual primary endpoints in prevention studies of cognitively unimpaired individuals at genetic risk for developing symptoms of Alzheimer’s disease. Alzheimer's Research & Therapy 15:1.
Crossref
Crossref
Naoki Suzuki, Ayumi Nishiyama, Hitoshi Warita & Masashi Aoki. (2022) Genetics of amyotrophic lateral sclerosis: seeking therapeutic targets in the era of gene therapy. Journal of Human Genetics 68:3, pages 131-152.
Crossref
Crossref
David A. Schoenfeld, Ritesh Ramchandani & Dianne M. Finkelstein. (2022) Designing a longitudinal clinical trial based on a composite endpoint: Sample size, monitoring, and adaptation. Statistics in Medicine 41:24, pages 4745-4755.
Crossref
Crossref
Marziye Eshghi, Yana Yunusova, Kathryn P. Connaghan, Bridget J. Perry, Marc F. Maffei, James D. Berry, Lorne Zinman, Sanjay Kalra, Lawrence Korngut, Angela Genge, Annie Dionne & Jordan R. Green. (2022) Rate of speech decline in individuals with amyotrophic lateral sclerosis. Scientific Reports 12:1.
Crossref
Crossref
Ruben P.A. van Eijk, Kit C.B. Roes, Leonard H. van den Berg & Ying Lu. (2022) Joint modeling of endpoints can be used to answer various research questions in randomized clinical trials. Journal of Clinical Epidemiology 147, pages 32-39.
Crossref
Crossref
Christina N. Fournier. (2022) Considerations for Amyotrophic Lateral Sclerosis (ALS) Clinical Trial Design. Neurotherapeutics 19:4, pages 1180-1192.
Crossref
Crossref
Merit E. Cudkowicz & Jeremy M. Shefner. (2022) Regulatory Approval in ALS; When Is a Single Study Enough?. Annals of Neurology 91:6, pages 737-739.
Crossref
Crossref
Jae-Yong Nam, Tae Yong Lee, Kwijoo Kim, Sehwan Chun, Min Sung Kim, Jin-Hong Shin, Jung-Joon Sung, Byoung Joon Kim, Byung-Jo Kim, Ki-Wook Oh, Kyung Suk Kim & Seung Hyun Kim. (2022) Efficacy and safety of Lenzumestrocel (Neuronata-R® inj.) in patients with amyotrophic lateral sclerosis (ALSUMMIT study): study protocol for a multicentre, randomized, double-blind, parallel-group, sham procedure-controlled, phase III trial. Trials 23:1.
Crossref
Crossref
Paolo Tornese, Stefania Lalli, Antoniangela Cocco & Alberto Albanese. (2022) Review of disease-modifying drug trials in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 521-529.
Crossref
Crossref
Ruben P A van Eijk, L H van den Berg & Ying Lu. (2022) Composite endpoint for ALS clinical trials based on patient preference: Patient-Ranked Order of Function (PROOF). Journal of Neurology, Neurosurgery & Psychiatry 93:5, pages 539-546.
Crossref
Crossref
Ruben P.A. van Eijk, Kit C.B. Roes, Inez de Greef‐van der Sandt, Leonard H. van den Berg & Ying Lu. (2022) Functional Loss and Mortality in Randomized Clinical Trials for Amyotrophic Lateral Sclerosis: To Combine, or Not to Combine—That is the Estimand. Clinical Pharmacology & Therapeutics 111:4, pages 817-825.
Crossref
Crossref
Merit E. Cudkowicz, Stacy R. Lindborg, Namita A. Goyal, Robert G. Miller, Matthew J. Burford, James D. Berry, Katharine A. Nicholson, Tahseen Mozaffar, Jonathan S. Katz, Liberty J. Jenkins, Robert H. Baloh, Richard A. Lewis, Nathan P. Staff, Margaret A. Owegi, Donald A. Berry, Yael Gothelf, Yossef S. Levy, Revital Aricha, Ralph Z. Kern, Anthony J. Windebank & Robert H. BrownJrJr. (2022)
A randomized
placebo‐controlled
phase 3 study of mesenchymal stem cells induced to secrete high levels of neurotrophic factors in amyotrophic lateral sclerosis
. Muscle & Nerve 65:3, pages 291-302.
Crossref
Crossref
Sabrina Paganoni, James D. Berry, Melanie Quintana, Eric Macklin, Benjamin R. Saville, Michelle A. Detry, Marianne Chase, Alexander V. Sherman, Hong Yu, Kristin Drake, Jinsy Andrews, Jeremy Shefner, Lori B. Chibnik, Matteo Vestrucci, Merit E. Cudkowicz, Eric Macklin, Melanie Quintana, Ben Saville, Michelle A. Detry, Lori Chibnik, Marie Abele Bind, James Chan, Matteo Vestrucci, Eduardo Locatelli, Gustavo Alameda, Sabrina Paganoni, Merit Cudkowicz, Alexandra McCaffrey, James Berry, Suma Babu, Katie Nicholson, Jennifer Scalia, Zachary Simmons, James Grogan, Xiaowei Su, Mansoureh Mamarabadi, Daragh Heitzman, Mohamad Asaad Nasri, Jonathan Katz, Liberty Jenkins, Kevin Felice, Charles Whitaker, Senda Ajroud‐Driss, Adam Quick, Stephen Kolb, N. P. Sarah Heintzman, Stanley H. Appel, Ericka (Simpson) Greene, Jason Thonhoff, Sheetal Shroff, Bing Liao, Stephen A. Goutman, Eva L. Feldman, Timothy Miller, N. P. Amber Malcolm, Daniel S. Newman, Ximena Arcila‐Londono, Kara Steijlen, Margaret Ayo Owegi, Robert H. BrownJrJr, Mehdi Ghasemi, Joseph Americo M. Fernandes, Ezequiel Piccione, Pariwat Thaisetthawatkul, Michael D. Weiss, Nassim Rad, Hristelina Ilieva, Piera Pasinelli, N. P. Judith Guarnieri, Shafeeq Ladha, Bill Jacobsen, Robert Bowser, Jeremy Shefner, Laura Foster, Carlayne Jackson, Jeffrey Rosenfeld, Karthikeyan Bhuvaneswaran, Lauren Elman, Colin Quinn, Jinsy Andrews, N. P. Julia Yasek, Dominic Fee, Terry Heiman‐Patterson, Anahita Deboo, Andrea Swenson, Christopher Nance, Tuan Vu, Niraja Suresh, Jerrica Farias, Jim Caress, Michael Cartwright, Kourosh Rezania, Matthew Elliott, Seward Rutkove, Courtney McIlduff, Jeffrey A. Cohen, Elijah Stommel, Jonathan Glass, Christina Fournier, Eufrosina Young, James P. Wymer, Volkan Granit, Michael Benatar, Richard Lewis, Matthew Burford, Frank Diaz, Nicholas J. Maragakis, Lora Clawson, Alpa Uchil, Kristen Riley, Betsy Mosmiller, Paul Twydell, Namita A. Goyal, Omar Jawdat, Duaa Jabari, Jeffrey Statland, Edward J. Kasarskis, James W. Russell, Peter Jin, David Walk, Sam Maiser, Jaimin Shah, Bjorn Oskarsson, Richard Bedlack, Xiaoyan Li, I‐Hweii Amy Chen, Nicholas Olney, Tracy Bazan, Ghazala Hayat, Gary L. Pattee, Peter D. Donofrio, Amanda C. Peltier, Jennifer Martinez‐Thompson, Nathan, Kristin Johnson, Raghav Govindarajan, Vovanti Jones, Tulio Bertorini, Clotilde Lagier Tourenne, Ghazaleh Sadri Vakili, Marianne Chase, Alex Sherman, Hong Yu, Derek Dagostino, Scott Bocchio, Matthew Eydinov, Kenneth Faulconer, Olga Kharakozova, Alexander Korin, Ilya Novak, Ervin Sinani, Natalia Tarasenko, Prasha Vigneswaran, Igor Katsovskiy, Isaac Whitworth, Yusra Wahab, Catherine Gladden, Aileen Shaughnessy, Eric Tustison, Katie Jentoft, Joe Ostrow, Sangwon Lim, Genevive Changkuon, Annette De Mattos, Janae Patterson, Robin Scott, Precious Figueroa‐Szostek, Lindsay Pothier, Brittney Harkey, Sofia DiStefano, Erin Kennedy, Abbey Bailey, Nicole DiOrio, Jacob Feulner, Matt Davis, Jassira Gomes, Marisa DiMarzio, Jennifer Henrique, Molly Benson, Stacey Grabert, Tessa Garozzo, Meghan Hall, Rebecca Randall, Mariah Connolly, Diana De Santiago, Courtney Lavery, Gale Kittle, Jenny Hamilton, Patrick Bolger, Ahmed Fetouh, Cornelia Kamp, Julie Kennedy, Catherine Small, Allison Bulat, Kristin Drake, Andrew McGarry & Margherita Torti. (2022) Adaptive Platform Trials to Transform Amyotrophic Lateral Sclerosis Therapy Development. Annals of Neurology 91:2, pages 165-175.
Crossref
Crossref
Leonor Cerdá Alberich, Juan Francisco Vázquez-Costa, Amadeo Ten-Esteve, Miguel Mazón & Luis Martí-Bonmatí. 2022. Neurodegenerative Diseases Biomarkers. Neurodegenerative Diseases Biomarkers
507
548
.
Nens van Alfen. (2021) Biomarkers to predict ALS progression – Can we get tools and people to work together?. Clinical Neurophysiology 132:10, pages 2677-2678.
Crossref
Crossref
Merit Cudkowicz, Angela Genge, Nicholas Maragakis, Susanne Petri, Leonard van den Berg, Valtteri V Aho, Toni Sarapohja, Mikko Kuoppamäki, Chris Garratt, Ammar Al-Chalabi, Matthew Kiernan, Susan Mathers, Robert Henderson, Merrilee Needham, David Schultz, Wolfgang Löscher, Nenad Mitrovic, Jakob Rath, Philip Van Damme, Jan L. De Bleecker, Stéphanie Delstanche, Wendy Johnston, Lorne Zinman, Colleen O'Connell, Genevieve Matte, Annie Dionne, Lawrence Korngut, John Turnbull, Hannu Laaksovirta, Manu Jokela, Tero Tapiola, Marie-Hélène Soriani, Philippe Couratier, William Camu, Philippe Corcia, Albert Ludolph, Julian Großkreutz, Thomas Meyer, Matthias Boentert, Berthold Schrank, Johannes Prudlo, Robert Untucht, Orla Hardiman, Gabriele Siciliano, Adriano Chio'Letizia Mazzini, Maurizio Inghilleri, Claudia Caponnetto, Gabriele Mora, Jesús S Mora Pardina, Eva Farrero Munoz, Juan F Vázquez Costa, Eduardo Aguera Morales, Luis Varona, Peter Andersen, Caroline Ingre, Rune Johansson, Aleksandar Radunovic, Carolyn Young, Suma Babu, Aziz Shaibani, Nathan Staff, Tuan Vu, Michael Rivner, Stephen Scelsa, Kumaraswamy Sivakumar, Waqar Waheed, Daragh Heitzman, Sandeep Rana, Gary Pattee, Senda Ajroud-Driss, Elham Bayat, Edward Kasarskis, Dale J Lange, Michael Elliott, Brent Harris, Kevin Felice, Michael T Pulley, Justin Kwan, Martin Brown, John Ravits, Matthew Burford, Chafic Karam, Timothy Miller, Jinsy Andrews, Todd Levine, Eduardo Locatelli, James Wymer, Richard Bedlack, Dominic Fee, Namita Goyal, Bjorn Oskarsson, Leo McCluskey, James Caress, Michael Weiss, Adam Quick, Mark Bromberg, David Lacomis, Stephen Goutman, Kourosh Rezania, Gaurav Guliani, Kimberly Goslin & Jonathan S Katz. (2021) Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): a randomised, double-blind, placebo-controlled phase 3 trial. The Lancet Neurology 20:10, pages 821-831.
Crossref
Crossref
Ruben P.A. van Eijk, Stavros Nikolakopoulos, Kit C.B. Roes, Lindsay Kendall, Steve S. Han, Arseniy Lavrov, Noam Epstein, Tessa Kliest, Adriaan D. de Jongh, Henk-Jan Westeneng, Ammar Al-Chalabi, Philip Van Damme, Orla Hardiman, Pamela J. Shaw, Christopher J. McDermott, Marinus J.C. Eijkemans & Leonard H. van den Berg. (2021) Innovating Clinical Trials for Amyotrophic Lateral Sclerosis. Neurology 97:11, pages 528-536.
Crossref
Crossref
Kristiana Salmon & Angela Genge. 2021. Spectrums of Amyotrophic Lateral Sclerosis. Spectrums of Amyotrophic Lateral Sclerosis
161
180
.
Federico Ranieri, Sara Mariotto, Raffaele Dubbioso & Vincenzo Di Lazzaro. (2021) Brain Stimulation as a Therapeutic Tool in Amyotrophic Lateral Sclerosis: Current Status and Interaction With Mechanisms of Altered Cortical Excitability. Frontiers in Neurology 11.
Crossref
Crossref
Danielle Beaulieu, Albert A. Taylor, Dustin Pierce, Jonavelle Cuerdo, Mark Schactman, Mike Keymer & David L. Ennist. 2021. Neurotherapeutics in the Era of Translational Medicine. Neurotherapeutics in the Era of Translational Medicine
333
366
.
Namita A. Goyal, James D. Berry, Anthony Windebank, Nathan P. Staff, Nicholas J. Maragakis, Leonard H. van den Berg, Angela Genge, Robert Miller, Robert H. Baloh, Ralph Kern, Yael Gothelf, Chaim Lebovits & Merit Cudkowicz. (2020) Addressing heterogeneity in amyotrophic lateral sclerosis CLINICAL TRIALS. Muscle & Nerve 62:2, pages 156-166.
Crossref
Crossref
Bruno Miranda, Marta Gromicho, Mariana Pereira, Susana Pinto, Michael Swash & Mamede de Carvalho. (2020) Diaphragmatic CMAP amplitude from phrenic nerve stimulation predicts functional decline in ALS. Journal of Neurology 267:7, pages 2123-2129.
Crossref
Crossref
Marie-Louise Zeissler, Vivien Li, Mahesh K.B. Parmar & Camille Buchholz Carroll. (2020) Is It Possible to Conduct a Multi-Arm Multi-Stage Platform Trial in Parkinson’s Disease: Lessons Learned from Other Neurodegenerative Disorders and Cancer. Journal of Parkinson's Disease 10:2, pages 413-428.
Crossref
Crossref
Christopher J McDermott. (2020) Stay at home with the amyotrophic lateral sclerosis functional rating scale. Journal of Neurology, Neurosurgery & Psychiatry 91:1, pages 7-7.
Crossref
Crossref
J. Verbeeck, E. Spitzer, T. Vries, G.A. Es, W. N. Anderson, N.M. Van Mieghem, M.B. Leon, G. Molenberghs & J. Tijssen. (2019) Generalized pairwise comparison methods to analyze (non)prioritized composite endpoints. Statistics in Medicine 38:30, pages 5641-5656.
Crossref
Crossref
Satoru Morimoto, Shinichi Takahashi, Komei Fukushima, Hideyuki Saya, Norihiro Suzuki, Masashi Aoki, Hideyuki Okano & Jin Nakahara. (2019) Ropinirole hydrochloride remedy for amyotrophic lateral sclerosis – Protocol for a randomized, double-blind, placebo-controlled, single-center, and open-label continuation phase I/IIa clinical trial (ROPALS trial). Regenerative Therapy 11, pages 143-166.
Crossref
Crossref
Christopher J. McDermott. (2019) Clinical trials in amyotrophic lateral sclerosis. Current Opinion in Neurology 32:5, pages 758-763.
Crossref
Crossref
Ruben P A van Eijk, James Rooney, Orla Hardiman & Leonard H van den Berg. (2019) Two heads are better than one: benefits of joint models for ALS trials. Journal of Neurology, Neurosurgery & Psychiatry 90:9, pages 1071-1072.
Crossref
Crossref
Jinsy A. Andrews, Lucie I. BruijnJeremy M. Shefner. (2019) ALS drug development guidances and trial guidelines. Neurology 93:2, pages 66-71.
Crossref
Crossref
Leonard H. van den BergEric SorensonGary GronsethEric A. MacklinJinsy AndrewsRobert H. BalohMichael BenatarJames D. BerryAdriano Chio, Philippe CorciaAngela GengeAmelie K. GubitzCatherine Lomen-HoerthChristopher J. McDermottErik P. PioroJeffrey Rosenfeld, Vincenzo SilaniMartin R. TurnerMarkus WeberBenjamin Rix BrooksRobert G. MillerHiroshi Mitsumoto. (2019) Revised Airlie House consensus guidelines for design and implementation of ALS clinical trials. Neurology 92:14.
Crossref
Crossref
Dianne M. Finkelstein & David A. Schoenfeld. (2018) Graphing the Win Ratio and its components over time. Statistics in Medicine 38:1, pages 53-61.
Crossref
Crossref
Dong-Chao Shen, Yin-Yan Xu, Bo Hou, Hong-Fei Tai, Kang Zhang, Shuang-Wu Liu, Zhi-Li Wang, Feng Feng, Ming-Sheng Liu & Li-Ying Cui. (2018) Monitoring Value of Multimodal Magnetic Resonance Imaging in Disease Progression of Amyotrophic Lateral Sclerosis. Chinese Medical Journal 131:24, pages 2904-2909.
Crossref
Crossref
Jennifer S. GewandterJoanna BrellGuido CavalettiPatrick M. DoughertyScott EvansLynn HowieMichael P. McDermottAnn O'MaraA. Gordon SmithDaniela Dastros-PiteiLynn R. GauthierSimon HaroutounianMatthew JarpeNathaniel P. KatzCharles LoprinziPaul RichardsonEllen M. Lavoie-SmithPatrick Y. WenDennis C. TurkRobert H. DworkinRoy Freeman. (2018) Trial designs for chemotherapy-induced peripheral neuropathy prevention. Neurology 91:9, pages 403-413.
Crossref
Crossref
Roland A Matsouaka, Aneesh B SinghalRebecca A Betensky. (2016) An optimal Wilcoxon–Mann–Whitney test of mortality and a continuous outcome. Statistical Methods in Medical Research 27:8, pages 2384-2400.
Crossref
Crossref
Stephen A. Goutman, Morton B. Brown, Jonathan D. Glass, Nicholas M. Boulis, Karl Johe, Tom Hazel, Merit Cudkowicz, Nazem Atassi, Lawrence Borges, Parag G. Patil, Stacey A. Sakowski & Eva L. Feldman. (2018) Long‐term Phase 1/2 intraspinal stem cell transplantation outcomes in ALS. Annals of Clinical and Translational Neurology 5:6, pages 730-740.
Crossref
Crossref
Ton Fang, Ahmad Al Khleifat, Jacques-Henri Meurgey, Ashley Jones, P Nigel Leigh, Gilbert Bensimon & Ammar Al-Chalabi. (2018) Stage at which riluzole treatment prolongs survival in patients with amyotrophic lateral sclerosis: a retrospective analysis of data from a dose-ranging study. The Lancet Neurology 17:5, pages 416-422.
Crossref
Crossref
Michael BenatarJoanne WuuPeter M. AndersenNazem AtassiWilliam DavidMerit CudkowiczDavid Schoenfeld. (2018)
Randomized, double-blind, placebo-controlled trial of arimoclomol in rapidly progressive
SOD1
ALS
. Neurology 90:7.
Crossref
Crossref
Keith M. SullivanEllen A. GoldmuntzLynette Keyes-ElsteinPeter A. McSweeneyAshley PinckneyBeverly WelchMaureen D. MayesRichard A. NashLeslie J. CroffordBarry EgglestonSharon CastinaLinda M. GriffithJulia S. GoldsteinDennis WallaceOana CraciunescuDinesh KhannaRodney J. FolzJonathan GoldinE. William St. ClairJames R. SeiboldKristine PhillipsShin MineishiRobert W. SimmsKaren BallenMark H. WenerGeorge E. GeorgesShelly HeimfeldChitra HosingStephen FormanSuzanne KafajaRichard M. SilverLeroy GriffingJan StorekSharon LeClercqRichard BrasingtonMary E. CsukaChristopher BredesonCarolyn Keever-TaylorRobyn T. DomsicM. Bashar KahalehThomas MedsgerDaniel E. Furst. (2018) Myeloablative Autologous Stem-Cell Transplantation for Severe Scleroderma. New England Journal of Medicine 378:1, pages 35-47.
Crossref
Crossref
Roland A. Matsouaka, Aneesh B. Singhal & Rebecca A. Betensky. 2018. New Frontiers of Biostatistics and Bioinformatics. New Frontiers of Biostatistics and Bioinformatics
3
40
.
James Rooney, Tom Burke, Alice Vajda, Mark Heverin & Orla Hardiman. (2017) What does the ALSFRS-R really measure? A longitudinal and survival analysis of functional dimension subscores in amyotrophic lateral sclerosis. Journal of Neurology, Neurosurgery & Psychiatry 88:5, pages 381-385.
Crossref
Crossref
Vincent Meininger, Angela Genge, Leonard H van den Berg, Wim Robberecht, Albert Ludolph, Adriano Chio, Seung H Kim, P Nigel Leigh, Matthew C Kiernan, Jeremy M Shefner, Claude Desnuelle, Karen E Morrison, Susanne Petri, Diane Boswell, Jane Temple, Rajat Mohindra, Matt Davies, Jonathan Bullman, Paul Rees, Arseniy Lavrov, Susanne Abdulla, Cathy Alsop, Francesca Barbieri, Stewart Bates, James D Berry, Stephan A Botez, Gaelle Bruneteau, Andrea Calvo, Rodrigo Refoios Camejo, William Camu, Deven Chauhan, Veronique Danel-Brunaud, Jerzy Daniluk, Annelot Dekker, Alain Destee, Matthew Devine, Stephen DeWall, Johannes Dorst, Giuseppe Fuda, Harutoshi Fujimura, Andreas Funke, Torsten Grehl, Julian Grosskreutz, Usha Gungabissoon, Robert Henderson, Peggy Ho, William Huynh, Saiju Jacob, Raul Juntas-Morales, Byung-Jo Kim, Xenia Kobeleva, Sonja Koerner, Stephen Kolb, Katja Kollewe, Lawrence Korngut, Geraldine Lautrette, Amy Lee, Anthony Lynch, Rami Massie, Genevieve Matte, Darryl Menezes, Stefano Milleri, Linda Nichols, Kazutoshi Nishiyama, Mieko Ogino, Chris Parkinson, Pierre-François Pradat, Tino Prell, Jeffrey Price, Eleanor Ramsey, Thomas M Ringer, Kristiana Salmon, Christen Shoesmith, Marie Helene Soriani, Marloes Stam, Erik Steinberg, Rob Stubbs, Herman Sullivan, Philip Van Damme, Michael van Es, Anne Visser, Mary Lou Watson, Andrea Sylvia Winkler, Lorne Zinman & Margie Zoing. (2017) Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet Neurology 16:3, pages 208-216.
Crossref
Crossref
Andrew McGarryMichael McDermottKarl KieburtzElisabeth A. de BlieckFlint BealKaren MarderChristopher RossIra ShoulsonPeter GilbertWilliam M. MalloneeMark GuttmanJoanne WojcieszekRajeev KumarMark S. LeDouxMary JenkinsH. Diana RosasMartha NanceKevin BiglanPeter ComoRichard M. DubinskyKathleen M. ShannonPadraig O'SuilleabhainKelvin ChouFrancis WalkerWayne MartinVicki L. WheelockElizabeth McCuskerJoseph JankovicCarlos SingerJuan Sanchez-RamosBurton ScottOksana SuchowerskyStewart A. FactorDonald S. HigginsJrJrEric MolhoFredy RevillaJohn N. CavinessJoseph H. FriedmanJoel S. PerlmutterAndrew FeiginKaren AndersonRamon RodriguezNikolaus R. McFarlandRussell L. MargolisEric S. FarbmanLynn A. RaymondValerie SuskiSandra KostykAmy ColcherLauren SeebergerEric EppingSherali EsmailNancy DiazWai Lun Alan FungAlan DiamondSamuel FrankPhilip HannaNeal HermanowiczLeon S. DureMerit CudkowiczJohn Adams, Mandar Jog, Christopher Hyson, Sarah Furtado, Andrew Duker, Melissa Armstrong, Christian Lachner, Hubert Fernandez, Michael S Okun, David Shprecher, Michael Cartwright, Clement Loy, Joohi Jiminez-Shahed, Bradley Robottom, Gregory Suter, Theresa Moore, Jane Forsyth, Andrea Hurt, Joann Belden, Katie Price, Diane Erickson, Breanna Nickels, Misty M Thompson, Linda Cole, Julie Megens, Emilija Makaji, Sara-Lynn Masse, Keith Malarick, Louisa Mook, Susan Maya, Alex Bender, Jessica Meyer, Puja Turakhia, Katherine Harwood, Kathryn Duderstadt, Sarah Lenarz, Judy Hamerlinck, Patricia Edern, Charlyne Hickey, Ashley Owens, Clare Gibbons, Carolyn Gray, Jean A Jaglin, Kimberly Janko, Holly Lawrence, Barbara Estes, Brigid Hayward, Allison Johnson, Amit Gode, Giselle Huet, Beverly Romero-Kersh, Kristine Wernette, Elizabeth Sullivan, Jamie Guyot, Julie Konkle, Christine O'Neill, Pamela King, Amanda Martin, John Bautista, Nicole Mans, Jane Griffith, Erica Surles, Sharon Halton, Alicia Palao, Nathalie Padron, Kolleen Elliott, Lynn Oelke, London Butterfield, Peggy Perry-Trice, Sarah Wyne, Carol Pantella, Lorelei Tainsh, Elaine Sperin, Sharon Evans, Maureen Gartner, Amy Duffy, Pamela Kristof, Lisa Niles, Steven Rainone, Angie Wernle, Ronda Clouse, Michelle Cines, Kelly Dustin, Maura Deeley, Stacy Merritt, Heather Ferreri, Alison McMurray, Alanna Sheinberg, Marsha Hughes-Gay, Kori Ladonna, Erin Chung, Jennifer Lee, Rachel Goldstein, Lindsay Esposito, Nicholas Scoglio, Matthew Grana, Carol Zimmerman, Lucia M Blasucci, William Thayer, Jennifer Hawkins, Julia Koch, Victoria Hunt, Jessica Bargoil, Ingrid Scott, Terry Tempkin, Linda Stewart, Emily Hayes, Donna Galea, Beatriz Belmar, Kylie Richardson, Christine Hunter, Ernesto Jimenez, Monica Quesada, Wendy Levy, Anita Blenke, Lisa Gauger, Joanna Stoner, Mary Lou Klimek, Barbara Sommerfeld, Mary Eglow, Katy Regan, Erin Neefus, Marie Malikowski, Teri Radam, Marci Zomok, Margaret Lannon, Rhonda Agramonte, Johanna Hartlein, Constance Nickerson, Samantha Gibson, Erin Hastings Monari, Camille Swartz, Anne Smith-Bova, Randi Jones, Catherine Wielinski, Shanthi Graham, David Gunn & Jillian McMillan. (2017) A randomized, double-blind, placebo-controlled trial of coenzyme Q10 in Huntington disease. Neurology 88:2, pages 152-159.
Crossref
Crossref
Ritesh RamchandaniDavid A. SchoenfeldDianne M. Finkelstein. (2016) Global rank tests for multiple, possibly censored, outcomes. Biometrics 72:3, pages 926-935.
Crossref
Crossref
Neil G. Simon. (2016) Lower motor neurons – Counting cogs in the ALS machine. Clinical Neurophysiology 127:7, pages 2668-2669.
Crossref
Crossref
R. Tortelli, M. Copetti, F. Panza, A. Fontana, R. Cortese, R. Capozzo, A. Introna, E. D'Errico, S. Zoccolella, S. Arcuti, D. Seripa, I. L. Simone & G. Logroscino. (2016) Time to generalization and prediction of survival in patients with amyotrophic lateral sclerosis: a retrospective observational study. European Journal of Neurology 23:6, pages 1117-1125.
Crossref
Crossref
Ching-Hua LuCorrie Macdonald-WallisElizabeth GrayNeil PearceAxel PetzoldNiklas NorgrenGavin GiovannoniPietro FrattaKatie SidleMark FishRichard OrrellRobin HowardKevin TalbotLinda GreensmithJens KuhleMartin R. TurnerAndrea Malaspina. (2015) Neurofilament light chain. Neurology 84:22, pages 2247-2257.
Crossref
Crossref
Katharine A. Nicholson, Merit E. Cudkowicz & James D. Berry. (2015) Clinical Trial Designs in Amyotrophic Lateral Sclerosis: Does One Design Fit All?. Neurotherapeutics 12:2, pages 376-383.
Crossref
Crossref
Roland A. MatsouakaRebecca A. Betensky. (2015) Power and sample size calculations for the Wilcoxon-Mann-Whitney test in the presence of death-censored observations. Statistics in Medicine 34:3, pages 406-431.
Crossref
Crossref
Jesse M. Cedarbaum, Diane Stephenson, Richard Rudick, Maria C. Carrillo, Glenn Stebbins, Douglas Kerr, Jill Heemskerk, Wendy R. Galpern, Petra Kaufmann, David Cella, Maria Isaac & Marc K. Walton. (2014) Commonalities and Challenges in the Development of Clinical Trial Measures in Neurology. Neurotherapeutics 12:1, pages 151-169.
Crossref
Crossref
Merit E Cudkowicz, Sarah Titus, Marianne Kearney, Hong Yu, Alexander Sherman, David Schoenfeld, Douglas Hayden, Amy Shui, Benjamin Brooks, Robin Conwit, Donna Felsenstein, David J Greenblatt, Myles Keroack, John T Kissel, Robert Miller, Jeffrey Rosenfeld, Jeffrey D Rothstein, Ericka Simpson, Nina Tolkoff-Rubin, Lorne Zinman & Jeremy M Shefner. (2014) Safety and efficacy of ceftriaxone for amyotrophic lateral sclerosis: a multi-stage, randomised, double-blind, placebo-controlled trial. The Lancet Neurology 13:11, pages 1083-1091.
Crossref
Crossref
Neil G. Simon, Martin R. Turner, Steve Vucic, Ammar Al‐Chalabi, Jeremy Shefner, Catherine Lomen‐Hoerth & Matthew C. Kiernan. (2014) Quantifying disease progression in amyotrophic lateral sclerosis. Annals of Neurology 76:5, pages 643-657.
Crossref
Crossref
Sabrina Paganoni, Merit Cudkowicz & James D Berry. (2014) Outcome measures in amyotrophic lateral sclerosis clinical trials. Clinical Investigation 4:7, pages 605-618.
Crossref
Crossref
Anne-Marie Wills, Jane Hubbard, Eric A Macklin, Jonathan Glass, Rup Tandan, Ericka P Simpson, Benjamin Brooks, Deborah Gelinas, Hiroshi Mitsumoto, Tahseen Mozaffar, Gregory P Hanes, Shafeeq S Ladha, Terry Heiman-Patterson, Jonathan Katz, Jau-Shin Lou, Katy Mahoney, Daniela Grasso, Robert Lawson, Hong Yu & Merit Cudkowicz. (2014) Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial. The Lancet 383:9934, pages 2065-2072.
Crossref
Crossref
Merit E Cudkowicz, Leonard H van den Berg, Jeremy M Shefner, Hiroshi Mitsumoto, Jesus S Mora, Albert Ludolph, Orla Hardiman, Michael E Bozik, Evan W Ingersoll, Donald Archibald, Adam L Meyers, Yingwen Dong, Wildon R Farwell & Douglas A Kerr. (2013) Dexpramipexole versus placebo for patients with amyotrophic lateral sclerosis (EMPOWER): a randomised, double-blind, phase 3 trial. The Lancet Neurology 12:11, pages 1059-1067.
Crossref
Crossref